

GR




ORIGINAL SUBMISSION

000004

Dr. Edward Iorio
10 Furnace Brook Parkway
Quincy, MA 02169
(617)-472-9300
Fax: (617)-472-9359
2/4/2002

Office of Premarket Approval (HFS-200)
Center for Food Safety and Applied Nutrition
Food and Drug Administration
200 C St, SW
Washington DC, 20204



GRAS Notice

Notifier:

Dr. Edward Iorio representing Jedwards International
10 Furnace Brook Parkway
Quincy, MA 02169

Location of supporting documentation:

10 Furnace Brook Parkway
Quincy, MA 02169

Small planktivorous pelagic fish body oil (SPPFBO), as a direct human food ingredient, is exempt from the premarket approval requirements of the Food, Drug, and Cosmetic Act because Jedwards International has determined that such use is GRAS. This determination is based upon a scientific procedure.

The data and information that are the basis for Jedwards International's GRAS determination are available for the Food and Drug Administration's review and copying at reasonable times at the above address or will be sent to FDA upon request.

000005

SPPFBO is made up of the body oil of small planktivorous pelagic fish, primarily sea-harvested Sardine (*Sardina pilchardus*) and Anchovy (*Cetengraulis mysticetus*). Menhaden, Sardine and Anchovy are all plankton eating fish closely related to Herring differing essentially only in size. SPPFBO is manufactured in the same manner as Menhaden oil and is virtually chemically identical in composition. Therefore, we submit that SPPFBO could be safely used as a substitute for Menhaden oil.

Upon examining the fatty acid profiles of Menhaden and SPPFBO the similarity is immediately apparent. (Data on Menhaden and Soybean oil obtained from the Menhaden oil GRAS petition; 21 CFR part 184 Docket No. 86G-0289 hereby incorporated by reference in its entirety).

Fatty acid profile (% weight):

<u>Fatty acid</u>	<u>Menhaden</u>	<u>SPPFBO</u>	<u>Soybean</u>
14:0	9.0	6.5	0.2
16:0	19.0	15.5	10.7
18:0	3.8	2.9	3.9
16:1	13.3	8.3	0.3
18:1	15.5	10.1	22.8
22:1	0.7	1.3	-
18:2	2.0	1.2	50.8
18:3	1.0	0.7	6.8
20:5	12.5	18.0	-
22:6	7.9	12.0	-

SPPFBO is desirable as a direct human food ingredient because of the high level of unsaturated fatty acids it contains naturally. There has been no formal determination of the health benefits of these substances nor is any health claim being made here. However, the FDA did conduct a study to evaluate the claim that consumption of omega-3 fatty acids is associated with a decreased risk of coronary heart disease. In the Federal Register of January 6, 1993 (58 FR 2682), the FDA published a final rule not to allow a direct claim due to conflicting evidence in the scientific literature but did acknowledge there was a large body of evidence that seemed to support the claim.

Since SPPFBO would be used as a possible substitute for the already approved Menhaden oil the Levels of use are established by the accepted levels for Menhaden oil in CFR Title 21 sec. 184.1472. The general population would be expected to consume these foods. Therefore, if there were any alterations to the approved method for use of Menhaden oil the same would apply to SPPFBO. The proposed uses for Menhaden oil and therefore SPPFBO as well are listed below:

<u>Category of food</u>	<u>Maximum level of use in food</u>
Cookies, crackers,	5.0 %
Breads, rolls (white & dark)	1.0%
Fruit pies, custard pies	7.0%
Cakes	10.0%
Cereals	4.0%
Fats, oils (but not in infant formulas)	20.0%
Yogurt	4.0%
Cheese products	5.0%
Frozen dairy products	5.0%
Meat products	10.0%
Egg products	5.0%
Fish products	20.0%
Condiments	5.0%
Soup mixes	3.0%
Snack foods	5.0%
Nut products	5.0%
Gravies, sauces	5.0%

This product has no single chemical name since, like other edible vegetable oils, it consists of a complex mixtures of glycerides, fatty acids, unsaponifiables and phospholipids. The CAS registry number for fish oils is 8016-13-5.

As in the case of other food lipids, SPPFBO consists mainly of a mixture of triglycerides of various long chain fatty acids with small amounts of mono and diglycerides. Triglycerides are esters of glycerol and fatty acids with chains of 14 to 22 carbon atoms. The fatty acids that characterize SPPFBO and other fish oil are similar to those in the various edible vegetable

000007

oils and animals fats differing principally in their relatively higher proportions of polyunsaturated fatty acids with five and six double bonds.

General Specifications for SPPFBO:

SPPFBO is a clear brilliant yellow oil. Odor and taste are fishy, but not rancid.

Specification	Value
Saponification value	Min 180 KOH/g
Iodine number	Min 150 g I/100g
Unsaponifiable matter	Max 1.3%
Free fatty acid	Max 0.5%
Peroxide value	Max 5 meq/Kg
Lead	Max 0.1 ppm
Mercury	Max 0.5 ppm

Specific method references are listed in CFR title 21 184.1472 Menhaden oil.

The processing of fish oils regardless of the species is standardized. The fish are cooked and pressed, the oil being separated from the expressed liquor and processed further in accordance with current good manufacturing practice using standard methods and equipment employed in the processing of other edible oils and fats. Refining involves winterization, neutralization, bleaching and deodorization.

Based on the findings of the Food and Drug Administrations report 21 CFR Part 184 [Docket No. 86G-0289] incorporated here by reference in its entirety consumption of fish oil is limited to 3 g/p/d of the omega-3 fatty acids EPA and DHA (EPA: Eicosapentaenoic Acid, DHA: Docosahexanoic Acid).

Jedwards International's GRAS determination is based upon a scientific procedure and supported by the following: (1) the precedent that the FDA has affirmed the oil produced from Menhaden, a type of planktivorous pelagic fish (Sec. 184.1472 of Title 21) GRAS as a direct food substance with specific limitations; (2) the scientific documentation and literature review, included in the Menhaden oil petition (Food additive petition for Menhaden oil under 21 CFR part 184 Docket No. 86G-0289 hereby incorporated by reference in its entirety) which discusses the oils of these types of fish. An exhaustive chemical analysis of fish oils can be found in the formal petition for GRAS status of Menhaden oil. Additionally, chemical techniques for the analysis of fish oils as well as copies of a very large body of scientific

literature from around the world are included in the petition and are available both at the FDA's archives as well as on record at Jedwards International. Supporting material was obtained by Jedwards International from the FDA freedom of information staff (HFI- 35, 5600 Fishers lane, Rockville, MD 20857).

Sardines and Anchovy are widely consumed as food products in the United States. Therefore, the fish oil derived from this type of fish is already consumed indirectly. Isolated fish body oils of planktivorous pelagic fish have been consumed in the United States as an encapsulated dietary supplement for at least two decades. Cod Liver oil has been widely consumed for a long time in sizeable daily doses and is identified as safe for human consumption by its inclusion in the U.S. Pharmacopeia.

Health concerns for fish oil are limited. However in the Food and Drug administrations report 21 CFR Part 184 [Docket No. 86G-0289] incorporated here by reference, a few health concerns are examined. The health concern for fish oils that were examined include: (1) the possibility that omega-3 fatty acids may cause increased bleeding times; (2) the possibility that non-insulin-dependent diabetics may experience increased glucose levels; (3) the possibility of increased LDL levels following fish oil consumption. The FDA examined the scientific documentation for these health concerns and found conflicting results. However, the body of evidence supported the conclusion that there appeared to be no statistically relevant risks as long as the consumption of fish oil is limited to 3 g/p/d of EPA and DHA.

Regards,



Dr. Edward James Iorio, Ph.D.
Special Projects Director
2/1/2002

000009

SUBMISSION END

000010



Ricker, Karin

From: Jedwards International [jedwardsinc@mindspring.com]
Sent: Monday, March 25, 2002 12:44 PM
To: Ricker, Karin
Subject: Re: withdrawal of GRAS 98

Okay Karin:

I will drop the original in the mail. Did your office receive the new submission? I believe I addressed all of the issues that Dr. Dinovi and I discussed. However, if anything is missing let me know. It would be easier for me to just correct the submission before you "officially" receive it than to have to withdraw it then resubmit it again. Of course I understand that you may have very strict protocols concerning receiving these documents.

Regards,

Ed

----- Original Message -----

From: "Ricker, Karin" <Karin.Ricker@cfsan.fda.gov>
To: "'Jedwards International'" <jedwardsinc@mindspring.com>
Sent: Monday, March 25, 2002 12:14 PM
Subject: RE: withdrawal of GRAS 98

> Hi Ed, just got your fax-thanks!

>

> -----Original Message-----

> From: Jedwards International [mailto:jedwardsinc@mindspring.com]
 > Sent: Monday, March 25, 2002 11:34 AM
 > To: Ricker, Karin
 > Subject: Re: withdrawal of GRAS 98

>

>

>

>

> Okay Karin:

>

> I will fax notice over at 12:30 pm today.

>

>

>

>

>

>

> ----- Original Message -----


> From: "Ricker, Karin" <Karin.Ricker@cfsan.fda.gov>
 > To: "'Jedwards International'" <jedwardsinc@mindspring.com>
 > Cc: "Kahl, Linda S" <Linda.Kahl@cfsan.fda.gov>
 > Sent: Monday, March 25, 2002 8:40 AM
 > Subject: RE: withdrawal of GRAS 98

>

000036

>
> > Perhaps you could include what the subject of your notice is and
when
you
> > submitted it. Otherwise I believe it would be sufficient. Please
let me
> > know when you fax it since I am not close to our fax machine (and
please
> > mail us the original). Thanks-Karin
> >
> > PS- you are right-you can not substitute one notice for another- you
have
> to
> > re- submit.
> >
> > -----Original Message-----
> > From: Jedwards International [mailto:jedwardsinc@mindspring.com]
> > Sent: Friday, March 22, 2002 2:52 PM
> > To: Ricker, Karin
> > Subject: Re: withdrawal of GRAS 98
> >
> >
> > Karin:
> >
> > Would this language be satisfactory:
> >
> > "This letter is formal notice that I am withdrawing GRAS notice 98.
> Please
> > cease evaluating the submission effective immediately."
> >
> > If this is okay I can fax you a letter as soon as you respond to
this
> email.
>
> > I sent via DHL a revised copy of the GRAS notice to Dr. Kahl. She
would
> > have received it by now. I believe that I addressed the issues that
Dr.
> > Dinovi brought up in our phone conversation. Essentially the main
changes
> > are that the table of uses has been adjusted down by 1/3 and the
term
> > "substitute" for menhaden has been removed. If the submission is
found
> > lacking in any way please let me know and I can make the appropriate
> > changes.
> >
> > Im not sure I fully understand all of your procedures on these
notices.
> > However, Im assuming I have to withdraw the previous one prior to
this
new
> > notice being evaluated. Am I correct in assuming we cant just
substitute
> the
> > new one for the old one and forgo the withdrawal protocol?
> >
> > Regards,
> >
> > Edward Iorio
> >
> >
> >
> >
> >

000037



Edward James Iorio
10 Furnace Brook Parkway
Quincy, MA 02169
3/25/2002

Food and Drug Administration
Center for Food Safety and Applied Nutrition
Office of Food Additive Safety
5100 Paint Branch Parkway
HFS-255
College Park, MD 20740-3835

Dear Dr. Karin Ricker:

This letter is formal notice that I am withdrawing GRAS notice 98 submitted on 2/4/2002 dealing with small planktivorous pelagic fish body oil (SPPFBO). Please cease evaluating the submission effective immediately.

Regards,

Edward James Iorio, Ph.D.

000040